Plasma hydroxyurea determined by gas chromatography-mass spectrometry.
Hydroxyurea treatment is efficiently used to ameliorate the clinical course of patients affected with sickle cell disease. To understand the patient's wide variation in the clinical response to that drug and monitor its plasma levels, a new method was developed and validated. Fifty microL plasmatic samples containing hydroxyurea are added with internal standard, deproteinized, evaporated to dryness, silanized, and analyzed by gas chromatography-mass spectrometry, which operates in the selected ion mode after electron impact fragmentation. Linearity was found to extend to at least 100mg/L. Over a 1-25mg/L concentration range, coefficients of variation for intra-day and inter-day precision are 5.3% and 7.7%, respectively. Plasma blank-samples reveal endogenous hydroxyurea at a level <or=0.2mg/L. The performances of the method, which is fast and simple, encounter the analytical goals needed for evaluation of hydroxyurea treatment and for pharmacokinetic studies.
Kettani
Tayeb
T
Medical Biochemistry Laboratory, Pharmaceutical Institute, Université Libre de Bruxelles, Belgium.
Cotton
Frédéric
F
Gulbis
Béatrice
B
Ferster
Alina
A
Kumps
Alain
A
D002648:Child; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D006801:Humans; D006918:Hydroxyurea / Q000097:blood*; D012015:Reference Standards; D015203:Reproducibility of Results
D006918:Hydroxyurea